BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Serra S, Horenstein AL, Vaisitti T, Brusa D, Rossi D, Laurenti L, D'Arena G, Coscia M, Tripodo C, Inghirami G, Robson SC, Gaidano G, Malavasi F, Deaglio S. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 2011;118:6141-52. [PMID: 21998208 DOI: 10.1182/blood-2011-08-374728] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Arruga F, Deaglio S. Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia. Handb Exp Pharmacol 2018;249:203-29. [PMID: 28275912 DOI: 10.1007/164_2017_12] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
2 Horenstein AL, Faini AC, Malavasi F. CD38 in the age of COVID-19: a medical perspective. Physiological Reviews 2021;101:1457-86. [DOI: 10.1152/physrev.00046.2020] [78495111110.1152/physrev.00046.2020','', '2218-6247')">Reference Citation Analysis]
3 Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pharmacology of Adenosine Receptors: The State of the Art. Physiol Rev 2018;98:1591-625. [PMID: 29848236 DOI: 10.1152/physrev.00049.2017] [Cited by in Crossref: 206] [Cited by in F6Publishing: 186] [Article Influence: 51.5] [Reference Citation Analysis]
4 Zhang B. Opportunities and challenges for anti-CD73 cancer therapy. Immunotherapy 2012;4:861-5. [PMID: 23046227 DOI: 10.2217/imt.12.83] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
5 Horenstein AL, Faini AC, Malavasi F. CD38 in the age of COVID-19: a medical perspective. Physiol Rev 2021;101:1457-86. [PMID: 33787351 DOI: 10.1152/physrev.00046.2020] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
6 Zeiser R, Vago L. Mechanisms of immune escape after allogeneic hematopoietic cell transplantation. Blood 2019;133:1290-7. [PMID: 30578254 DOI: 10.1182/blood-2018-10-846824] [Cited by in Crossref: 45] [Cited by in F6Publishing: 44] [Article Influence: 11.3] [Reference Citation Analysis]
7 Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 2017;6:e1386829. [PMID: 29209573 DOI: 10.1080/2162402X.2017.1386829] [Cited by in Crossref: 124] [Cited by in F6Publishing: 77] [Article Influence: 24.8] [Reference Citation Analysis]
8 Pianko MJ, Liu Y, Bagchi S, Lesokhin AM. Immune checkpoint blockade for hematologic malignancies: a review. Stem Cell Investig 2017;4:32. [PMID: 28529947 DOI: 10.21037/sci.2017.03.04] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 7.2] [Reference Citation Analysis]
9 Xu S, Shao QQ, Sun JT, Yang N, Xie Q, Wang DH, Huang QB, Huang B, Wang XY, Li XG, Qu X. Synergy between the ectoenzymes CD39 and CD73 contributes to adenosinergic immunosuppression in human malignant gliomas. Neuro Oncol 2013;15:1160-72. [PMID: 23737488 DOI: 10.1093/neuonc/not067] [Cited by in Crossref: 67] [Cited by in F6Publishing: 58] [Article Influence: 7.4] [Reference Citation Analysis]
10 Mandapathil M. Adenosine-mediated immunosuppression in patients with squamous cell carcinoma of the head and neck. HNO 2016;64:303-9. [DOI: 10.1007/s00106-016-0137-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
11 de Andrade Mello P, Coutinho-Silva R, Savio LEB. Multifaceted Effects of Extracellular Adenosine Triphosphate and Adenosine in the Tumor-Host Interaction and Therapeutic Perspectives. Front Immunol 2017;8:1526. [PMID: 29184552 DOI: 10.3389/fimmu.2017.01526] [Cited by in Crossref: 45] [Cited by in F6Publishing: 42] [Article Influence: 9.0] [Reference Citation Analysis]
12 Allard B, Beavis PA, Darcy PK, Stagg J. Immunosuppressive activities of adenosine in cancer. Curr Opin Pharmacol 2016;29:7-16. [PMID: 27209048 DOI: 10.1016/j.coph.2016.04.001] [Cited by in Crossref: 131] [Cited by in F6Publishing: 132] [Article Influence: 21.8] [Reference Citation Analysis]
13 Longhi MS, Robson SC, Bernstein SH, Serra S, Deaglio S. Biological functions of ecto-enzymes in regulating extracellular adenosine levels in neoplastic and inflammatory disease states. J Mol Med (Berl) 2013;91:165-72. [PMID: 23292173 DOI: 10.1007/s00109-012-0991-z] [Cited by in Crossref: 47] [Cited by in F6Publishing: 50] [Article Influence: 5.2] [Reference Citation Analysis]
14 Festino L, Vanella V, Trojaniello C, Ascierto PA. Selecting immuno-oncology–based drug combinations – what should we be considering? Expert Review of Clinical Pharmacology 2018;11:971-85. [DOI: 10.1080/17512433.2018.1518713] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
15 Vaisitti T, Audrito V, Serra S, Buonincontri R, Sociali G, Mannino E, Pagnani A, Zucchetto A, Tissino E, Vitale C, Coscia M, Usai C, Pepper C, Gattei V, Bruzzone S, Deaglio S. The enzymatic activities of CD38 enhance CLL growth and trafficking: implications for therapeutic targeting. Leukemia 2015;29:356-68. [PMID: 24990614 DOI: 10.1038/leu.2014.207] [Cited by in Crossref: 23] [Cited by in F6Publishing: 23] [Article Influence: 2.9] [Reference Citation Analysis]
16 Hock BD, MacPherson SA, McKenzie JL. Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells. PLoS One 2017;12:e0172858. [PMID: 28257435 DOI: 10.1371/journal.pone.0172858] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
17 Nevedomskaya E, Perryman R, Solanki S, Syed N, Mayboroda OA, Keun HC. A Systems Oncology Approach Identifies NT5E as a Key Metabolic Regulator in Tumor Cells and Modulator of Platinum Sensitivity. J Proteome Res 2016;15:280-90. [PMID: 26629888 DOI: 10.1021/acs.jproteome.5b00793] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
18 Poggi A, Musso A, Dapino I, Zocchi MR. Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. Immunol Lett 2014;159:55-72. [PMID: 24657523 DOI: 10.1016/j.imlet.2014.03.001] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 8.3] [Reference Citation Analysis]
19 Arruga F, Serra S, Vitale N, Guerra G, Papait A, Baffour Gyau B, Tito F, Efremov D, Vaisitti T, Deaglio S. Targeting of the A2A adenosine receptor counteracts immunosuppression in vivo in a mouse model of chronic lymphocytic leukemia. Haematologica 2021;106:1343-53. [PMID: 32299906 DOI: 10.3324/haematol.2019.242016] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Vaisitti T, Arruga F, Deaglio S. Targeting the Adenosinergic Axis in Chronic Lymphocytic Leukemia: A Way to Disrupt the Tumor Niche? Int J Mol Sci 2018;19:E1167. [PMID: 29649100 DOI: 10.3390/ijms19041167] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Ziebart A, Huber U, Jeske S, Laban S, Doescher J, Hoffmann TK, Brunner C, Jackson EK, Schuler PJ. The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma. Oncotarget 2018;9:5834-47. [PMID: 29464038 DOI: 10.18632/oncotarget.23533] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
22 Allard D, Chrobak P, Allard B, Messaoudi N, Stagg J. Targeting the CD73-adenosine axis in immuno-oncology. Immunol Lett 2019;205:31-9. [PMID: 29758241 DOI: 10.1016/j.imlet.2018.05.001] [Cited by in Crossref: 56] [Cited by in F6Publishing: 57] [Article Influence: 14.0] [Reference Citation Analysis]
23 Allard D, Allard B, Gaudreau PO, Chrobak P, Stagg J. CD73-adenosine: a next-generation target in immuno-oncology. Immunotherapy 2016;8:145-63. [PMID: 26808918 DOI: 10.2217/imt.15.106] [Cited by in Crossref: 76] [Cited by in F6Publishing: 73] [Article Influence: 12.7] [Reference Citation Analysis]
24 Chen S, Wainwright DA, Wu JD, Wan Y, Matei DE, Zhang Y, Zhang B. CD73: an emerging checkpoint for cancer immunotherapy. Immunotherapy 2019;11:983-97. [PMID: 31223045 DOI: 10.2217/imt-2018-0200] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 10.7] [Reference Citation Analysis]
25 Zeiser R, Beelen DW, Bethge W, Bornhäuser M, Bug G, Burchert A, Christopeit M, Duyster J, Finke J, Gerbitz A, Klusmann JH, Kobbe G, Lübbert M, Müller-tidow C, Platzbecker U, Rösler W, Sauer M, Schmid C, Schroeder T, Stelljes M, Kröger N, Müller LP. Biology-Driven Approaches to Prevent and Treat Relapse of Myeloid Neoplasia after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 2019;25:e128-40. [DOI: 10.1016/j.bbmt.2019.01.016] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
26 Liu O, Xu J, Ding G, Liu D, Fan Z, Zhang C, Chen W, Ding Y, Tang Z, Wang S. Periodontal ligament stem cells regulate B lymphocyte function via programmed cell death protein 1. Stem Cells. 2013;31:1371-1382. [PMID: 23553748 DOI: 10.1002/stem.1387] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 6.4] [Reference Citation Analysis]
27 Rovatti PE, Gambacorta V, Lorentino F, Ciceri F, Vago L. Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation. Front Immunol 2020;11:147. [PMID: 32158444 DOI: 10.3389/fimmu.2020.00147] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
28 D'Arrigo P, Tufano M, Rea A, Vigorito V, Novizio N, Russo S, Romano MF, Romano S. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. Curr Med Chem 2020;27:2402-48. [PMID: 30398102 DOI: 10.2174/0929867325666181106114421] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
29 He Y, Zhao Y, Nelson DM, Klippel A, Reily MD. NMR-Based Assay for the Ex Vivo Determination of Soluble CD73 Activity in Serum. Anal Chem 2020;92:14501-8. [PMID: 32985862 DOI: 10.1021/acs.analchem.0c02630] [Reference Citation Analysis]
30 Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev 2017;276:121-44. [PMID: 28258700 DOI: 10.1111/imr.12528] [Cited by in Crossref: 348] [Cited by in F6Publishing: 346] [Article Influence: 69.6] [Reference Citation Analysis]
31 Adams JL, Smothers J, Srinivasan R, Hoos A. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discov 2015;14:603-22. [PMID: 26228631 DOI: 10.1038/nrd4596] [Cited by in Crossref: 242] [Cited by in F6Publishing: 206] [Article Influence: 34.6] [Reference Citation Analysis]
32 Horenstein AL, Chillemi A, Zaccarello G, Bruzzone S, Quarona V, Zito A, Serra S, Malavasi F. A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes. Oncoimmunology 2013;2:e26246. [PMID: 24319640 DOI: 10.4161/onci.26246] [Cited by in Crossref: 133] [Cited by in F6Publishing: 135] [Article Influence: 14.8] [Reference Citation Analysis]
33 Antonioli L, Blandizzi C, Pacher P, Haskó G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013;13:842-57. [PMID: 24226193 DOI: 10.1038/nrc3613] [Cited by in Crossref: 415] [Cited by in F6Publishing: 386] [Article Influence: 46.1] [Reference Citation Analysis]
34 Khan NA, Garg AD, Agostinis P, Swinnen JV. Drug-induced ciliogenesis in pancreatic cancer cells is facilitated by the secreted ATP-purinergic receptor signaling pathway. Oncotarget 2018;9:3507-18. [PMID: 29423062 DOI: 10.18632/oncotarget.23335] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Forconi F, Moss P. Perturbation of the normal immune system in patients with CLL. Blood 2015;126:573-81. [PMID: 26084672 DOI: 10.1182/blood-2015-03-567388] [Cited by in Crossref: 161] [Cited by in F6Publishing: 159] [Article Influence: 23.0] [Reference Citation Analysis]
36 Huang J, Long Z, Lin W, Liao X, Xie Y, Liu L, Ma W. Integrative omics analysis of p53-dependent regulation of metabolism. FEBS Lett 2018;592:380-93. [PMID: 29323703 DOI: 10.1002/1873-3468.12968] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
37 Ladoire S, Hannani D, Vetizou M, Locher C, Aymeric L, Apetoh L, Kepp O, Kroemer G, Ghiringhelli F, Zitvogel L. Cell-death-associated molecular patterns as determinants of cancer immunogenicity. Antioxid Redox Signal 2014;20:1098-116. [PMID: 23394620 DOI: 10.1089/ars.2012.5133] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.7] [Reference Citation Analysis]
38 Audrito V, Serra S, Brusa D, Mazzola F, Arruga F, Vaisitti T, Coscia M, Maffei R, Rossi D, Wang T, Inghirami G, Rizzi M, Gaidano G, Garcia JGN, Wolberger C, Raffaelli N, Deaglio S. Extracellular nicotinamide phosphoribosyltransferase (NAMPT) promotes M2 macrophage polarization in chronic lymphocytic leukemia. Blood 2015;125:111-23. [DOI: 10.1182/blood-2014-07-589069] [Cited by in Crossref: 97] [Cited by in F6Publishing: 100] [Article Influence: 13.9] [Reference Citation Analysis]
39 Allard B, Turcotte M, Stagg J. CD73-generated adenosine: orchestrating the tumor-stroma interplay to promote cancer growth. J Biomed Biotechnol 2012;2012:485156. [PMID: 23125525 DOI: 10.1155/2012/485156] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 5.8] [Reference Citation Analysis]
40 Hajizadeh F, Masjedi A, Heydarzedeh Asl S, Karoon Kiani F, Peydaveisi M, Ghalamfarsa G, Jadidi-Niaragh F, Sevbitov A. Adenosine and adenosine receptors in colorectal cancer. Int Immunopharmacol 2020;87:106853. [PMID: 32755765 DOI: 10.1016/j.intimp.2020.106853] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
41 de Lourdes Mora-García M, López-Cisneros S, Gutiérrez-Serrano V, García-Rocha R, Weiss-Steider B, Hernández-Montes J, Sánchez-Peña HI, Ávila-Ibarra LR, Don-López CA, Muñóz-Godínez R, Pineda DBT, Chacón-Salinas R, Vallejo-Castillo L, Pérez-Tapia SM, Monroy-García A. HPV-16 Infection Is Associated with a High Content of CD39 and CD73 Ectonucleotidases in Cervical Samples from Patients with CIN-1. Mediators Inflamm 2019;2019:4651627. [PMID: 31205451 DOI: 10.1155/2019/4651627] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
42 Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev 2017;276:121-44. [PMID: 28258700 DOI: 10.1111/imr.12528] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Adams J, Duffy K, Moore M, Yang J. Cancer Immunotherapy—An Emerging Field That Bridges Oncology and Immunology Research. Comprehensive Medicinal Chemistry III. Elsevier; 2017. pp. 357-94. [DOI: 10.1016/b978-0-12-409547-2.12400-x] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Cai Y, Feng L, Wang X. Targeting the tumor promoting effects of adenosine in chronic lymphocytic leukemia. Critical Reviews in Oncology/Hematology 2018;126:24-31. [DOI: 10.1016/j.critrevonc.2018.03.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
45 Ren ZH, Lin CZ, Cao W, Yang R, Lu W, Liu ZQ, Chen YM, Yang X, Tian Z, Wang LZ, Li J, Wang X, Chen WT, Ji T, Zhang CP. CD73 is associated with poor prognosis in HNSCC. Oncotarget 2016;7:61690-702. [PMID: 27557512 DOI: 10.18632/oncotarget.11435] [Cited by in Crossref: 39] [Cited by in F6Publishing: 41] [Article Influence: 6.5] [Reference Citation Analysis]
46 O'Neill AT, Chakraverty R. Graft Versus Leukemia: Current Status and Future Perspectives. J Clin Oncol 2021;39:361-72. [PMID: 33434054 DOI: 10.1200/JCO.20.01801] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
47 Liu N, Fang XD, Vadis Q. CD73 as a novel prognostic biomarker for human colorectal cancer. J Surg Oncol 2012;106:918-9; author reply 920. [PMID: 22585744 DOI: 10.1002/jso.23159] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
48 Burnstock G, Di Virgilio F. Purinergic signalling and cancer. Purinergic Signal. 2013;9:491-540. [PMID: 23797685 DOI: 10.1007/s11302-013-9372-5] [Cited by in Crossref: 171] [Cited by in F6Publishing: 173] [Article Influence: 21.4] [Reference Citation Analysis]
49 Serra S, Vaisitti T, Audrito V, Bologna C, Buonincontri R, Chen SS, Arruga F, Brusa D, Coscia M, Jaksic O, Inghirami G, Rossi D, Furman RR, Robson SC, Gaidano G, Chiorazzi N, Deaglio S. Adenosine signaling mediates hypoxic responses in the chronic lymphocytic leukemia microenvironment. Blood Adv 2016;1:47-61. [PMID: 29296695 DOI: 10.1182/bloodadvances.2016000984] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
50 Ghiringhelli F, Bruchard M, Chalmin F, Rébé C. Production of adenosine by ectonucleotidases: a key factor in tumor immunoescape. J Biomed Biotechnol 2012;2012:473712. [PMID: 23133312 DOI: 10.1155/2012/473712] [Cited by in Crossref: 52] [Cited by in F6Publishing: 57] [Article Influence: 5.2] [Reference Citation Analysis]
51 Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17:709-724. [PMID: 29059149 DOI: 10.1038/nrc.2017.86] [Cited by in Crossref: 250] [Cited by in F6Publishing: 233] [Article Influence: 50.0] [Reference Citation Analysis]
52 Augustin RC, Leone RD, Naing A, Fong L, Bao R, Luke JJ. Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy. J Immunother Cancer 2022;10:e004089. [PMID: 35135866 DOI: 10.1136/jitc-2021-004089] [Reference Citation Analysis]
53 Maffei R, Bulgarelli J, Fiorcari S, Bertoncelli L, Martinelli S, Guarnotta C, Castelli I, Deaglio S, Debbia G, De Biasi S, Bonacorsi G, Zucchini P, Narni F, Tripodo C, Luppi M, Cossarizza A, Marasca R. The monocytic population in chronic lymphocytic leukemia shows altered composition and deregulation of genes involved in phagocytosis and inflammation. Haematologica 2013;98:1115-23. [PMID: 23349302 DOI: 10.3324/haematol.2012.073080] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 6.9] [Reference Citation Analysis]
54 Beavis PA, Stagg J, Darcy PK, Smyth MJ. CD73: a potent suppressor of antitumor immune responses. Trends in Immunology 2012;33:231-7. [DOI: 10.1016/j.it.2012.02.009] [Cited by in Crossref: 229] [Cited by in F6Publishing: 216] [Article Influence: 22.9] [Reference Citation Analysis]
55 Ranjbar MA, Ranjbar Z, Zahed M, Nikookar N. CD73 a novel marker for the diagnosis of benign and malignant salivary gland tumors. J Clin Exp Dent 2019;11:e213-8. [PMID: 31001389 DOI: 10.4317/jced.54918] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
56 Trubiani O, Horenstein AL, Caciagli F, Caputi S, Malavasi F, Ballerini P. Expression of P2X7 ATP receptor mediating the IL8 and CCL20 release in human periodontal ligament stem cells. J Cell Biochem 2014;115:1138-46. [PMID: 24851271 DOI: 10.1002/jcb.24756] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
57 Horenstein AL, Bracci C, Morandi F, Malavasi F. CD38 in Adenosinergic Pathways and Metabolic Re-programming in Human Multiple Myeloma Cells: In-tandem Insights From Basic Science to Therapy. Front Immunol 2019;10:760. [PMID: 31068926 DOI: 10.3389/fimmu.2019.00760] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 9.7] [Reference Citation Analysis]
58 Sociali G, Raffaghello L, Magnone M, Zamporlini F, Emionite L, Sturla L, Bianchi G, Vigliarolo T, Nahimana A, Nencioni A, Raffaelli N, Bruzzone S. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model. Oncotarget 2016;7:2968-84. [PMID: 26658104 DOI: 10.18632/oncotarget.6502] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 6.3] [Reference Citation Analysis]
59 Schmetterer KG, Goldhahn K, Ziegler LS, Gerner MC, Schmidt RLJ, Themanns M, Zebedin-Brandl E, Trapin D, Leitner J, Pickl WF, Steinberger P, Schwarzinger I, Marculescu R. Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro. Front Immunol 2019;10:1790. [PMID: 31417563 DOI: 10.3389/fimmu.2019.01790] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
60 He T, Brocca-Cofano E, Gillespie DG, Xu C, Stock JL, Ma D, Policicchio BB, Raehtz KD, Rinaldo CR, Apetrei C, Jackson EK, Macatangay BJ, Pandrea I. Critical Role for the Adenosine Pathway in Controlling Simian Immunodeficiency Virus-Related Immune Activation and Inflammation in Gut Mucosal Tissues. J Virol 2015;89:9616-30. [PMID: 26178986 DOI: 10.1128/JVI.01196-15] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
61 Kellner M, von Neubeck B, Czogalla B, Feederle R, Vick B, Jeremias I, Zeidler R. A Novel Anti-CD73 Antibody That Selectively Inhibits Membrane CD73 Shows Antitumor Activity and Induces Tumor Immune Escape. Biomedicines 2022;10:825. [DOI: 10.3390/biomedicines10040825] [Reference Citation Analysis]
62 Huang Y, Gu Z, Fan Y, Zhai G, Zhao X, Sun Q, Shi Y, Lin G. Inhibition of the adenosinergic pathway: the indispensable part of oncological therapy in the future. Purinergic Signal 2019;15:53-67. [PMID: 30809739 DOI: 10.1007/s11302-018-9641-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
63 Yu YI, Wang W, Song L, Hu W, Dong C, Pei H, Zhou G, Yue Z. Ecto-5'-nucleotidase expression is associated with the progression of renal cell carcinoma. Oncol Lett 2015;9:2485-94. [PMID: 26137095 DOI: 10.3892/ol.2015.3138] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
64 Vaisitti T, Arruga F, Guerra G, Deaglio S. Ectonucleotidases in Blood Malignancies: A Tale of Surface Markers and Therapeutic Targets. Front Immunol 2019;10:2301. [PMID: 31636635 DOI: 10.3389/fimmu.2019.02301] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
65 Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol Med 2013;19:355-67. [PMID: 23601906 DOI: 10.1016/j.molmed.2013.03.005] [Cited by in Crossref: 561] [Cited by in F6Publishing: 549] [Article Influence: 62.3] [Reference Citation Analysis]
66 Yang H, Yao F, Davis PF, Tan ST, Hall SRR. CD73, Tumor Plasticity and Immune Evasion in Solid Cancers. Cancers (Basel) 2021;13:E177. [PMID: 33430239 DOI: 10.3390/cancers13020177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
67 Rossi D, Trifonov V, Fangazio M, Bruscaggin A, Rasi S, Spina V, Monti S, Vaisitti T, Arruga F, Famà R. The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. J Exp Med. 2012;209:1537-1551. [PMID: 22891273 DOI: 10.1084/jem.20120904] [Cited by in Crossref: 253] [Cited by in F6Publishing: 229] [Article Influence: 25.3] [Reference Citation Analysis]
68 Allard B, Turcotte M, Stagg J. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer. Expert Opin Ther Targets 2014;18:863-81. [PMID: 24798880 DOI: 10.1517/14728222.2014.915315] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 3.6] [Reference Citation Analysis]
69 Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ, Stagg J. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci U S A 2013;110:11091-6. [PMID: 23776241 DOI: 10.1073/pnas.1222251110] [Cited by in Crossref: 268] [Cited by in F6Publishing: 251] [Article Influence: 29.8] [Reference Citation Analysis]
70 Perez DR, Sklar LA, Chigaev A, Matlawska-Wasowska K. Drug repurposing for targeting cyclic nucleotide transporters in acute leukemias - A missed opportunity. Semin Cancer Biol 2021;68:199-208. [PMID: 32044470 DOI: 10.1016/j.semcancer.2020.02.004] [Reference Citation Analysis]
71 Bönner F, Borg N, Burghoff S, Schrader J. Resident cardiac immune cells and expression of the ectonucleotidase enzymes CD39 and CD73 after ischemic injury. PLoS One 2012;7:e34730. [PMID: 22514659 DOI: 10.1371/journal.pone.0034730] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
72 Allard D, Charlebois R, Gilbert L, Stagg J, Chrobak P. CD73-A2a adenosine receptor axis promotes innate B cell antibody responses to pneumococcal polysaccharide vaccination. PLoS One 2018;13:e0191973. [PMID: 29377929 DOI: 10.1371/journal.pone.0191973] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Chillemi A, Zaccarello G, Quarona V, Ferracin M, Ghimenti C, Massaia M, Horenstein AL, Malavasi F. Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule. Mol Med 2013;19:99-108. [PMID: 23615966 DOI: 10.2119/molmed.2013.00009] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 5.0] [Reference Citation Analysis]
74 Lin YL, Ip PP, Liao F. CCR6 Deficiency Impairs IgA Production and Dysregulates Antimicrobial Peptide Production, Altering the Intestinal Flora. Front Immunol 2017;8:805. [PMID: 28744287 DOI: 10.3389/fimmu.2017.00805] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
75 Morandi F, Horenstein AL, Chillemi A, Quarona V, Chiesa S, Imperatori A, Zanellato S, Mortara L, Gattorno M, Pistoia V, Malavasi F. CD56brightCD16- NK Cells Produce Adenosine through a CD38-Mediated Pathway and Act as Regulatory Cells Inhibiting Autologous CD4+ T Cell Proliferation. J Immunol 2015;195:965-72. [PMID: 26091716 DOI: 10.4049/jimmunol.1500591] [Cited by in Crossref: 75] [Cited by in F6Publishing: 72] [Article Influence: 10.7] [Reference Citation Analysis]
76 Abruzzo LV, Herling CD, Calin GA, Oakes C, Barron LL, Banks HE, Katju V, Keating MJ, Coombes KR. Trisomy 12 chronic lymphocytic leukemia expresses a unique set of activated and targetable pathways. Haematologica 2018;103:2069-78. [PMID: 29976738 DOI: 10.3324/haematol.2018.190132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
77 Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, Vandenberghe P, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology 2020;9:1703449. [PMID: 32002302 DOI: 10.1080/2162402X.2019.1703449] [Cited by in Crossref: 58] [Cited by in F6Publishing: 41] [Article Influence: 29.0] [Reference Citation Analysis]
78 Allard B, Longhi MS, Robson SC, Stagg J. The ectonucleotidases CD39 and CD73: Novel checkpoint inhibitor targets. Immunol Rev 2017;276:121-44. [PMID: 28258700 DOI: 10.1111/imr.12528] [Reference Citation Analysis]
79 Lai YP, Kuo LC, Lin BR, Lin HJ, Lin CY, Chen YT, Hsiao PW, Chang HT, Ko PC, Chen HC, Chang HY, Lu J, Ho HN, Wu-Hsieh BA, Kung JT, Chen SC. CD28 engagement inhibits CD73-mediated regulatory activity of CD8+ T cells. Commun Biol 2021;4:595. [PMID: 34011962 DOI: 10.1038/s42003-021-02119-9] [Reference Citation Analysis]
80 Regateiro FS, Cobbold SP, Waldmann H. CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Exp Immunol 2013;171:1-7. [PMID: 23199317 DOI: 10.1111/j.1365-2249.2012.04623.x] [Cited by in Crossref: 98] [Cited by in F6Publishing: 101] [Article Influence: 10.9] [Reference Citation Analysis]
81 Ghalamfarsa G, Kazemi MH, Raoofi Mohseni S, Masjedi A, Hojjat-farsangi M, Azizi G, Yousefi M, Jadidi-niaragh F. CD73 as a potential opportunity for cancer immunotherapy. Expert Opinion on Therapeutic Targets 2018;23:127-42. [DOI: 10.1080/14728222.2019.1559829] [Cited by in Crossref: 40] [Cited by in F6Publishing: 44] [Article Influence: 10.0] [Reference Citation Analysis]
82 Chernogorova P, Zeiser R. Ectonucleotidases in solid organ and allogeneic hematopoietic cell transplantation. J Biomed Biotechnol 2012;2012:208204. [PMID: 23125523 DOI: 10.1155/2012/208204] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
83 Baghbani E, Noorolyai S, Shanehbandi D, Mokhtarzadeh A, Aghebati-Maleki L, Shahgoli VK, Brunetti O, Rahmani S, Shadbad MA, Baghbanzadeh A, Silvestris N, Baradaran B. Regulation of immune responses through CD39 and CD73 in cancer: Novel checkpoints. Life Sci 2021;282:119826. [PMID: 34265363 DOI: 10.1016/j.lfs.2021.119826] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
84 Shali S, Yu J, Zhang X, Wang X, Jin Y, Su M, Liao X, Yu J, Zhi X, Zhou P. Ecto-5'-nucleotidase (CD73) is a potential target of hepatocellular carcinoma. J Cell Physiol 2019;234:10248-59. [PMID: 30417547 DOI: 10.1002/jcp.27694] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
85 Barwe SP, Quagliano A, Gopalakrishnapillai A. Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia. Semin Oncol 2017;44:101-12. [PMID: 28923207 DOI: 10.1053/j.seminoncol.2017.06.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
86 Dulphy N, Henry G, Hemon P, Khaznadar Z, Dombret H, Boissel N, Bensussan A, Toubert A. Contribution of CD39 to the immunosuppressive microenvironment of acute myeloid leukaemia at diagnosis. Br J Haematol 2014;165:722-5. [PMID: 24666252 DOI: 10.1111/bjh.12774] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
87 Antonioli L, Yegutkin GG, Pacher P, Blandizzi C, Haskó G. Anti-CD73 in cancer immunotherapy: awakening new opportunities. Trends Cancer 2016;2:95-109. [PMID: 27014745 DOI: 10.1016/j.trecan.2016.01.003] [Cited by in Crossref: 119] [Cited by in F6Publishing: 113] [Article Influence: 19.8] [Reference Citation Analysis]
88 Griggio V, Mandili G, Vitale C, Capello M, Macor P, Serra S, Castella B, Peola S, Foglietta M, Drandi D, Omedé P, Sblattero D, Cappello P, Chiarle R, Deaglio S, Boccadoro M, Novelli F, Massaia M, Coscia M. Humoral immune responses toward tumor-derived antigens in previously untreated patients with chronic lymphocytic leukemia. Oncotarget 2017;8:3274-88. [PMID: 27906678 DOI: 10.18632/oncotarget.13712] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
89 Rizzo R, Audrito V, Vacca P, Rossi D, Brusa D, Stignani M, Bortolotti D, D'Arena G, Coscia M, Laurenti L, Forconi F, Gaidano G, Mingari MC, Moretta L, Malavasi F, Deaglio S. HLA-G is a component of the chronic lymphocytic leukemia escape repertoire to generate immune suppression: impact of the HLA-G 14 base pair (rs66554220) polymorphism. Haematologica 2014;99:888-96. [PMID: 24362551 DOI: 10.3324/haematol.2013.095281] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 3.4] [Reference Citation Analysis]
90 Gao ZW, Dong K, Zhang HZ. The roles of CD73 in cancer. Biomed Res Int 2014;2014:460654. [PMID: 25126561 DOI: 10.1155/2014/460654] [Cited by in Crossref: 67] [Cited by in F6Publishing: 91] [Article Influence: 8.4] [Reference Citation Analysis]
91 Alizadeh M, Safarzadeh A, Hoseini SA, Piryaei R, Mansoori B, Hajiasgharzadeh K, Baghbanzadeh A, Baradaran B. The potentials of immune checkpoints for the treatment of blood malignancies. Crit Rev Oncol Hematol 2020;153:103031. [PMID: 32622320 DOI: 10.1016/j.critrevonc.2020.103031] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
92 Jin H, Lee JS, Kim DC, Ko YS, Lee GW, Kim HJ. Increased Extracellular Adenosine in Radiotherapy-Resistant Breast Cancer Cells Enhances Tumor Progression through A2AR-Akt-β-Catenin Signaling. Cancers (Basel) 2021;13:2105. [PMID: 33925516 DOI: 10.3390/cancers13092105] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
93 Arruga F, Gyau BB, Iannello A, Vitale N, Vaisitti T, Deaglio S. Immune Response Dysfunction in Chronic Lymphocytic Leukemia: Dissecting Molecular Mechanisms and Microenvironmental Conditions. Int J Mol Sci 2020;21:E1825. [PMID: 32155826 DOI: 10.3390/ijms21051825] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 12.0] [Reference Citation Analysis]
94 Allahyari SE, Hajizadeh F, Zekiy AO, Mansouri N, Gilan PS, Mousavi SM, Masjedi A, Hassannia H, Ahmadi M, Mohammadi H, Yousefi M, Izadi S, Zolbanin NM, Jafari R, Jadidi-Niaragh F. Simultaneous inhibition of CD73 and IL-6 molecules by siRNA-loaded nanoparticles prevents the growth and spread of cancer. Nanomedicine 2021;34:102384. [PMID: 33771704 DOI: 10.1016/j.nano.2021.102384] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Borea PA, Gessi S, Merighi S, Vincenzi F, Varani K. Pathological overproduction: the bad side of adenosine. Br J Pharmacol 2017;174:1945-60. [PMID: 28252203 DOI: 10.1111/bph.13763] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 11.2] [Reference Citation Analysis]
96 Jakobsen JS, Laursen LG, Schuster MB, Pundhir S, Schoof E, Ge Y, d'Altri T, Vitting-Seerup K, Rapin N, Gentil C, Jendholm J, Theilgaard-Mönch K, Reckzeh K, Bullinger L, Döhner K, Hokland P, Fitzgibbon J, Porse BT. Mutant CEBPA directly drives the expression of the targetable tumor-promoting factor CD73 in AML. Sci Adv 2019;5:eaaw4304. [PMID: 31309149 DOI: 10.1126/sciadv.aaw4304] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
97 Yu J, Liao X, Li L, Lv L, Zhi X, Yu J, Zhou P. A preliminary study of the role of extracellular -5′- nucleotidase in breast cancer stem cells and epithelial-mesenchymal transition. In Vitro Cell Dev Biol -Animal 2017;53:132-40. [DOI: 10.1007/s11626-016-0089-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
98 Ohta A. A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment. Front Immunol. 2016;7:109. [PMID: 27066002 DOI: 10.3389/fimmu.2016.00109] [Cited by in Crossref: 174] [Cited by in F6Publishing: 170] [Article Influence: 29.0] [Reference Citation Analysis]